戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ients were treated, and 13 received the full preoperative chemotherapy.
2 re registered in the study, and 138 received preoperative chemotherapy.
3 e operative morbidity and mortality by using preoperative chemotherapy.
4 Each patient was treated with four cycles of preoperative chemotherapy.
5 ncer who underwent resection of CCLM without preoperative chemotherapy.
6 T10 protocol and therapy with more intensive preoperative chemotherapy.
7 ix patients with stage IIIB disease received preoperative chemotherapy.
8  28% displayed a good histologic response to preoperative chemotherapy.
9 sectable gastric adenocarcinoma who received preoperative chemotherapy.
10  calendar period of surgery, and response to preoperative chemotherapy.
11 ing and histologic assessment of response to preoperative chemotherapy.
12 mber and diameter, extrahepatic disease, and preoperative chemotherapy.
13 ng system, lack validation in the setting of preoperative chemotherapy.
14                   59.8% of patients received preoperative chemotherapy.
15 ge of the primary, and the administration of preoperative chemotherapy.
16 er resection for colorectal metastases after preoperative chemotherapy.
17 a is possible in many patients after initial preoperative chemotherapy.
18 physicians prefer a short course of systemic preoperative chemotherapy.
19 ve histologically positive lymph nodes after preoperative chemotherapy.
20 f Pediatric Oncology in Europe in regards to preoperative chemotherapy.
21  the time of diagnosis patients' response to preoperative chemotherapy.
22 s (727 after excluding patients who received preoperative chemotherapy, 202 after 1:1 PS-matching).
23        Two hundred sixteen patients received preoperative chemotherapy, 227 underwent immediate surge
24 6.4%; P=0.037), as well as lower response to preoperative chemotherapy (63.9% vs 85.2%; P=0.006).
25       Of 102 patients, 84% and 85% completed preoperative chemotherapy, 73% and 70% underwent resecti
26              The regimen with more intensive preoperative chemotherapy achieved a modest increase in
27 tricted to "benchmark" patients, selected on preoperative chemotherapy administration and response.
28 carcinoma in situ (DCIS) after completion of preoperative chemotherapy affects the outcome of patient
29                    Of 30 patients completing preoperative chemotherapy, all had tumor regression and
30 e excluded, two because they were undergoing preoperative chemotherapy and 11 because of the presence
31 l: 14.9 months for the patients who received preoperative chemotherapy and 16.1 months for those who
32 adequate data , 213 were assigned to receive preoperative chemotherapy and 227 to undergo immediate s
33  was 78% for the regimen with more intensive preoperative chemotherapy and 73% for the control arm.
34                                              Preoperative chemotherapy and chemoradiation have also b
35 linical stage II or III disease treated with preoperative chemotherapy and curative-intent resection,
36 rbB-2 expression with histologic response to preoperative chemotherapy and event-free survival in thi
37 utcomes for 378 patients treated with modern preoperative chemotherapy and hepatectomy were analyzed.
38 e residual disease at surgery after standard preoperative chemotherapy and HER2-targeted therapy shou
39 nt, and the relationship between response to preoperative chemotherapy and outcome were also evaluate
40 APC and PIK3CA predicts inferior response to preoperative chemotherapy and poor survival in patients
41 Although EPP as part of trimodality therapy (preoperative chemotherapy and postoperative radiation) i
42 of newer chemotherapeutic agents, the use of preoperative chemotherapy and radiotherapy, and the use
43  and PIK3CA mutations in patients undergoing preoperative chemotherapy and resection for colorectal l
44  Pathologic response predicts survival after preoperative chemotherapy and resection of CLM.
45 chemotherapy predicts patient survival after preoperative chemotherapy and resection of colorectal li
46 in WT, in addition to histologic response to preoperative chemotherapy and tumor stage.
47 y scans of consecutive patients who received preoperative chemotherapy and/or (chemo)radiation before
48                       All patients completed preoperative chemotherapy, and 26 completed preoperative
49 in the surgery-only arm and 62 months in the preoperative chemotherapy arm (hazard ratio, 0.79; 95% C
50 h AJCC stage IIIB extremity STS treated with preoperative chemotherapy between 1986 and 1990 at The U
51 vascular or biliary invasion) are reduced by preoperative chemotherapy, but their impact on survival
52 ic radiation therapy (50 to 60 Gy; arm A) or preoperative chemotherapy (cisplatin/etoposide [PE]; thr
53         No patient in the early era received preoperative chemotherapy, compared with 64 in the late
54 hile preserving renal tissue by intensifying preoperative chemotherapy, completing definitive surgery
55                                              Preoperative chemotherapy consisted of four courses of h
56 nts (6 months to 18 years) were treated with preoperative chemotherapy consisting of 6 weeks of vincr
57 tion was to administer up to five courses of preoperative chemotherapy consisting of fluorouracil (50
58                            Tumor response to preoperative chemotherapy correlates with outcome and co
59 ptor status, histologic grade, and number of preoperative chemotherapy cycles had good discrimination
60     The success of breast conservation after preoperative chemotherapy depends on careful patient sel
61 le gastric cancer were randomized to receive preoperative chemotherapy followed by adequate gastrecto
62 OS for chemotherapy alone, cystectomy alone, preoperative chemotherapy followed by cystectomy, and cy
63 is made with a biopsy, treatment consists of preoperative chemotherapy followed by definitive surgery
64 lti-institutional randomized trial comparing preoperative chemotherapy followed by surgery with surge
65 ents with primary breast cancer treated with preoperative chemotherapy followed by surgery; have avai
66            In one patient, who had undergone preoperative chemotherapy for a mass that was initially
67                             After completing preoperative chemotherapy for a median of 7.1 months (ra
68 status who underwent hepatic resection after preoperative chemotherapy for CCLM (1990 to 2015).
69 ate the feasibility, safety, and efficacy of preoperative chemotherapy for colon cancer.
70 l vein embolization (5%, 9%, 9%, P = 0.001), preoperative chemotherapy for colorectal liver metastase
71       However, there were trends in favor of preoperative chemotherapy for DFS and OS in women less t
72                                              Preoperative chemotherapy for patients randomly assigned
73 opsy can be performed either before or after preoperative chemotherapy for patients with clinical N0
74                                              Preoperative chemotherapy for radiologically staged, loc
75 ients whose tumour showed a poor response to preoperative chemotherapy (>/=10% viable tumour) improve
76 tients with objective tumor regression after preoperative chemotherapy had improved survival.
77 ents who had initial tumor size < or = 2 cm, preoperative chemotherapy had no impact on volume of bre
78 al tumor size >2.0 cm, patients who received preoperative chemotherapy had significantly smaller volu
79                         The increased use of preoperative chemotherapy has raised new questions conce
80  larger breast tumors, patients treated with preoperative chemotherapy have less extensive resection,
81 0 months for surgery alone and 33 months for preoperative chemotherapy (hazard ratio, 0.80; 95% CI, 0
82 NBC patients treated with anthracycline-only preoperative chemotherapy, high CD73 gene expression was
83            Long-term follow-up confirms that preoperative chemotherapy improves survival in operable
84 tal neoadjuvant therapy (TNT) protocols (ie, preoperative chemotherapy in addition to radiotherapy) m
85                                              Preoperative chemotherapy in operable breast cancer has
86 ally assess benefits and risks of the use of preoperative chemotherapy in patients presenting with co
87  value of an optimal morphologic response to preoperative chemotherapy in patients undergoing chemoth
88    OEO2 is a randomized, controlled trial of preoperative chemotherapy in patients undergoing radical
89 ET is valuable for monitoring the effects of preoperative chemotherapy in patients with locally advan
90                                              Preoperative chemotherapy, in addition to other common r
91  The degree of tumor necrosis in response to preoperative chemotherapy is a reliable prognostic facto
92  localized esophageal cancer, whether or not preoperative chemotherapy is administered, only an R0 re
93                                              Preoperative chemotherapy is as effective as postoperati
94                                         This preoperative chemotherapy is feasible and can also be pr
95 ms' tumour when the histological response to preoperative chemotherapy is incorporated into the risk
96                                              Preoperative chemotherapy is increasingly being used for
97 resected primary tumor following a period of preoperative chemotherapy is predictive of subsequent ev
98                                              Preoperative chemotherapy is the conventional primary tr
99 ts with LA/BR PDAC, which includes prolonged preoperative chemotherapy, is associated with a high inc
100 ectomy between 2010 and 2018 after receiving preoperative chemotherapy (n = 36; 12%), (chemo)radiatio
101 th good histologic response with intensified preoperative chemotherapy, no improvement in EFS was obs
102        A statistically significant impact of preoperative chemotherapy on outcomes was observed in th
103 g those that occurred during the interval of preoperative chemotherapy (one of the five also had a su
104                                              Preoperative chemotherapy or chemoradiation has been acc
105 rcinoma specimens from patients treated with preoperative chemotherapy or chemoradiation therapy, we
106 ssion correlated with histologic response to preoperative chemotherapy or event-free survival.
107 ephrectomy from 1989 to 2006 did not receive preoperative chemotherapy or radiation therapy and under
108       Significant predictors of SSI included preoperative chemotherapy (OR = 1.94 [95% CI, 1.16-3.25]
109 ed with 91% (90 of 99) of patients following preoperative chemotherapy (p=0.10).
110                               Independent of preoperative chemotherapy regimen, optimal morphologic r
111                                              Preoperative chemotherapy-related hematologic toxicity a
112 ith fluorine-18 fluorodeoxyglucose (FDG) for preoperative chemotherapy response in patients with loca
113                         Two did not complete preoperative chemotherapy secondary to cardiovascular to
114 tment approach including standardized 3-drug preoperative chemotherapy, surgical resection within 12
115 tients who underwent hepatic resection after preoperative chemotherapy that included bevacizumab at a
116         Although OS and PFS were higher with preoperative chemotherapy, the differences did not reach
117 lly advanced breast carcinoma (LABC) receive preoperative chemotherapy to provide early systemic trea
118                     All 13 patients received preoperative chemotherapy to reduce the size of the prim
119 of the study included pathologic response to preoperative chemotherapy, toxicity, and survival.
120 h of liver resection, malignant indications, preoperative chemotherapy treatment, elements of metabol
121 ilar demographics, diagnoses, comorbidities, preoperative chemotherapy treatments, and extent of part
122 .99; 95% CI, 0.97-1.00), less sensitivity to preoperative chemotherapy (very sensitive vs refractory
123 ological response (> 90% tumour necrosis) to preoperative chemotherapy was about 29% with both regime
124 peratively, and 56.3%, 20.5%, and 15.9% when preoperative chemotherapy was administered alone.
125                                              Preoperative chemotherapy was administered in 68% of cas
126                                              Preoperative chemotherapy was administered to 77 patient
127              Compared with cystectomy alone, preoperative chemotherapy was associated with a signific
128                       Histologic response to preoperative chemotherapy was determined by morphometric
129                       Gradually, the idea of preoperative chemotherapy was extended to include patien
130                                  Response to preoperative chemotherapy was observed in 29 of 72 patie
131 ted with oxaliplatin and/or irinotecan-based preoperative chemotherapy were eligible for the study.
132 surgically resected CLM patients without any preoperative chemotherapy were included with a median fo
133 for patients with breast cancer treated with preoperative chemotherapy were reviewed.
134                         Complications during preoperative chemotherapy were seen in five patients (tu
135 red fifty-eight patients (38.9%) received no preoperative chemotherapy, whereas 248 patients (61.1%)
136                                              Preoperative chemotherapy with a combination of cisplati
137                         The patient receives preoperative chemotherapy with doxorubicin and cyclophos
138 atients started and 89% (85 of 95) completed preoperative chemotherapy with grade 3-4 gastrointestina
139          This article analyzes the impact of preoperative chemotherapy with mitomycin, ifosfamide, an
140  trials have again demonstrated tolerance to preoperative chemotherapy with no increase in operative
141                  We report on feasibility of preoperative chemotherapy with or without radiation ther
142  in 26 countries who had received 4 weeks of preoperative chemotherapy with vincristine and actinomyc
143                                              Preoperative chemotherapy (with or without radiotherapy)
144 his study was to determine if more intensive preoperative chemotherapy would increase the proportion

 
Page Top